arrow
J

Jan D. Lünemann

University of British Columbia
H指数:51
被引数:1.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Practical Guidance on Initiating and Switching Targeted Immunotherapies in Generalised Myasthenia Gravis: A German–Austrian Expert Opinion Paper

关于在全身性重症肌无力中启动和转换靶向免疫疗法:一项德奥专家意见论文

2026-09-100
OAAI
Meningococcal prophylaxis in neurological diseases treated with complement inhibitors: an expert consensus for Germany, Austria, and Switzerland

在用补体抑制剂治疗的神经疾病中实施脑膜炎球菌预防:德国、奥地利和瑞士的专家共识

2026-05-080
PRE
Emerging CSF and Serum Biomarkers in Multiple Sclerosis

多发性硬化中新兴的脑脊液和血清生物标志物

2026-05-010
PRE
Cellular and humoral vaccination response under immunotherapies—German consensus on vaccination strategies in neurological autoimmune diseases

细胞和体液疫苗接种反应在免疫疗法下——德国关于神经自身免疫性疾病疫苗接种策略的共识

2025-12-120
OA
Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and Eculizumab

拉伏珠单抗和阿巴西普对经典和替代补体通路的抑制

2025-11-010
OAAI
Calprotectin and neurofilament serum levels correlate with treatment response in myasthenia gravis under intensified therapy–A pilot study

钙卫蛋白和神经丝蛋白血清水平与重症肌无力在强化治疗下的治疗反应相关——一项试点研究

2025-09-090
OAAI
Suboptimal B-cell depletion is associated with progression independent of relapse activity in multiple sclerosis patients treated with ocrelizumab

奥瑞利珠单抗治疗的多发性硬化患者中,次优B细胞清除与独立于复发活动的疾病进展相关。

2025-04-030
PRE
Aberrant Complement Activation Is Associated With Structural Brain Damage in Multiple Sclerosis
2025-03-010
PRE
Complement Activation Profiles Predict Clinical Outcomes in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease
2025-01-010
PRE